

**REMARKS**

Claims 1-5, 15 and 31 are pending in this application, with claims 6-14 and 16-30 having been withdrawn from consideration as being directed to a non-elected invention.

By this Amendment, claims 1 and 15 have been amended and claim 31 has been newly added. The Brief Description of the Drawings has been amended to better reflect the numbering on the Figures. No new matter has been introduced by these amendments.

The specification was objected to for not containing references to drawings. Applicants submit that this objection has been overcome by the amendments to the specification presented herein.

Claims 1-5 and 15 were rejected under 35 U.S.C. § 112, first paragraph, for lack of enablement.

The Office Action indicated that the pathophysiology of pancreatitis is considered unclear by those skilled in the art, that known treatments only address symptoms of pancreatitis, and that the specification does not teach those skilled in the art how to prevent pancreatitis without requiring undue experimentation. Without conceding the propriety of this position, Applicants submit that this rejection is moot in view of the amendments to claims 1 and 15 set forth above, and respectfully request that this rejection be withdrawn.

The Office Action further indicated that the specification does not teach those skilled in the art how to make or screen metabolically stable analogues of spermidine without undue experimentation. Without conceding the propriety of this rejection, Applicants submit that it is also moot in view of the amendments to claim 15, and respectfully request

that the rejection be withdrawn.

Claims 1-5 and 15 were rejected under 35 U.S.C. § 102(a) as being anticipated by Rasanen et al. (Journal of Biological Chemistry, Vol. 277, No. 42, pp. 39867-39872).

Applicants submit the attached Declaration under 37 C.F.R. § 1.132 to establish that the Rasanen et al. article is describing Applicants' own work, and does not qualify as prior art under 35 U.S.C. § 102(a) because it is not "by others." Applicants therefore respectfully request that this rejection be withdrawn.

Claims 1-5 and 15 were rejected under 35 U.S.C. § 102(b) as being anticipated by Jakus et al. (U.S. Patent No. 5,344,846, hereinafter "Jakus"). To the extent it is still applicable in view of the amendments set forth herein, Applicants respectfully traverse this rejection.

Jakus discloses compositions and methods for inhibiting proliferative cell growth by inhibiting deoxyhypusine synthase. The compositions may include spermidine, 1-methylspermidine, and spermine. Jakus fails to disclose or suggest methods of using spermidine to **treat** pancreatitis. Applicants therefore respectfully request that this rejection be withdrawn.


In view of the foregoing remarks and amendments, reconsideration and allowance of the pending claims is respectfully requested.

**CONCLUSION**

In view of the foregoing amendments and remarks, reconsideration of the application, withdrawal of the outstanding rejections, allowance of Claims and the prompt issuance of a Notice of Allowability are respectfully solicited. Should the Examiner believe anything further is desirable in order to place this application in better condition for allowance, the Examiner is requested to contact the undersigned at the telephone number listed below.

In the event this paper is not considered to be timely filed, Applicants respectfully petition for an appropriate extension of time. Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300, making reference to Attorney Docket No. 108306-00034.

Respectfully submitted,

  
Dawn C. Russell  
Registration No. 44,751  
Attorney for Applicants

Customer Number 004372  
ARENT FOX PLLC  
1050 Connecticut Avenue, NW  
Suite 400  
Washington, DC 20036-5339  
Telephone: 202-857-6000  
Fax: 202-638-4810

RJB/DCR:ksm

Enclosures: Declaration Under 37 C.F.R. § 1.132  
Petition for Extension of Time (one month)